Streetbeat News

Analyst Ratings

HLF

Mizuho analyst John Baumgartner has maintained a Neutral rating on Herbalife (NYSE:HLF) and reduced the price target from $14 to $12.

Portfolio Pulse from Benzinga Newsdesk

February 17, 2024 | 12:06 am

EPAM

Mizuho analyst Sean Kennedy maintains a Buy rating on EPAM Systems (NYSE:EPAM) and raises the price target from $340 to $345.

Portfolio Pulse from Benzinga Newsdesk

February 17, 2024 | 12:04 am

DASH

Mizuho analyst James Lee maintains a Buy rating on DoorDash (NASDAQ:DASH) and raises the price target from $140 to $152, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:58 pm

CFLT

Mizuho analyst Gregg Moskowitz maintains a Buy rating on Confluent (NASDAQ:CFLT) and raises the price target from $34 to $38.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:56 pm

AMAT

Mizuho analyst Vijay Rakesh maintains a Buy rating on Applied Materials (AMAT) and increases the price target from $185 to $225, indicating a positive outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:55 pm

ITCI

Mizuho analyst Graig Suvannavejh maintains a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $76 to $82.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:53 pm

IMCR

Mizuho analyst Graig Suvannavejh has maintained a Buy rating on Immunocore Holdings (IMCR) and increased the price target from $72 to $86. This adjustment reflects a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:52 pm

HRMY

Mizuho analyst Graig Suvannavejh maintains a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and raises the price target from $33 to $42.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:50 pm

EYPT

Mizuho analyst Graig Suvannavejh maintains a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and raises the price target from $30 to $39.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:48 pm

AXSM

Mizuho analyst Graig Suvannavejh maintains a Buy rating on Axsome Therapeutics (AXSM) and raises the price target from $90 to $112.

Portfolio Pulse from Benzinga Newsdesk

February 16, 2024 | 11:48 pm